Orchard Therapeutics
101 Seaport Boulevard, 7th Floor
Boston
MA
02210
United States
Website: http://www.orchard-tx.com/
Email: careers@orchard-tx.com
205 articles about Orchard Therapeutics
-
Clinical Catch-Up: May 11-15
5/18/2020
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look. -
Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I
5/15/2020
Orchard Therapeutics, a global gene therapy leader, announced new interim data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, an ex vivo autologous hematopoietic stem cell gene therapy in development for the treatment of mucopolysaccharidosis type I at the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy.
-
The culling of one-fourth of its employees is expected to save the company approximately $125 million through the end of 2021.
-
Orchard Therapeutics Unveils New Strategic Plan and Reports First Quarter 2020 Financial Results
5/7/2020
Orchard Therapeutics, a global gene therapy leader, announced a new strategic plan to realize the potential of the hematopoietic stem cell gene therapy approach and reported its financial results for the quarter ended March 31, 2020.
-
Clinical Catch-Up: April 27-May 1
5/4/2020
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look. -
Orchard Therapeutics to Webcast Conference Call of First Quarter 2020 Financial Results
5/1/2020
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 7, 2020, at 8:00 a.m. ET to report its first quarter 2020 financial results and other business updates. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at orchard-tx.com. The conference call can be accessed by
-
Orchard Therapeutics Announces Eight Presentations Across Gene Therapy Portfolio at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting
4/29/2020
Most Comprehensive Presentation of Orchard Clinical Data to Date; Spans Five Disease Areas and Highlights Broad Applicability of Hematopoietic Stem Cell Gene Therapy Approach
-
Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome (MPS-IIIA)
4/27/2020
Orchard Therapeutics, a global gene therapy leader, announced that the first patient has been dosed in an open-label, proof-of-concept investigational study of OTL-201, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of mucopolysaccharidosis type IIIA.
-
Orchard Therapeutics Outlines Business Impact of COVID-19
3/31/2020
Orchard Therapeutics, a global leader in gene therapy, provided an update on its business and operations, outlining how the COVID-19 pandemic has and may continue to impact the company’s development programs and timelines, product supply, commercial operations and financial position.
-
Orchard Therapeutics Appoints Company Founder and Gene Therapy Pioneer Bobby Gaspar, M.D., Ph.D., as New Chief Executive Officer
3/18/2020
Orchard Therapeutics announced that company founder and gene therapy pioneer Bobby Gaspar, M.D., Ph.D., has been named chief executive officer, effective immediately.
-
Orchard Therapeutics Reports 2019 Financial Results and Reviews Key Strategic Priorities for 2020
2/27/2020
Orchard Therapeutics (Nasdaq: ORTX), a global leader in gene therapy, today reported business highlights and financial results for the year ended December 31, 2019, as well as 2020 strategic priorities and upcoming milestones.
-
Orchard Therapeutics to Present at Investor Conferences in March
2/26/2020
Orchard Therapeutics (Nasdaq: ORTX), a global leader in gene therapy, today announced that members of the management team will present at the following investor conferences in March:
-
Orchard Therapeutics to Webcast Conference Call of 2019 Financial Results
2/20/2020
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, February 27, 2020, at 8:00 a.m. ET to report its 2019 financial results and other business updates.
-
Orchard Therapeutics Announces Presentation of Clinical Data from Neurometabolic Franchise at 16th Annual WORLD Symposium
2/10/2020
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced upcoming presentations from its neurometabolic franchise at the 16th Annual WORLD Symposium on February 10-13 in Orlando, FL
-
Orchard Therapeutics Appoints Industry Veteran Steven Altschuler, M.D. to its Board of Directors
2/3/2020
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Steven Altschuler, M.D., to its board of directors.
-
Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD)
1/29/2020
Early Clinical Data Support ex vivo Hematopoietic Stem Cell Gene Therapy as a Potentially Promising Treatment Option for X-CGD
-
Orchard Therapeutics Highlights 2020 Strategic Priorities
1/13/2020
Commercial Preparations on Track for Potential 2020 EU Launch of OTL-200 for Metachromatic Leukodystrophy (MLD) with U.S. Regulatory Filing Expected Late 2020 / Early 2021
-
Orchard Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/6/2020
Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the company is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference
-
Orchard Therapeutics Showcases Clinical Data at the 61st American Society of Hematology Annual Meeting
12/8/2019
Orchard Therapeutics, a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, will be presenting new registrational data from multiple programs at the 61st American Society of Hematology Annual Meeting being held December 7-10, 2019 in Orlando, FL.
-
Orchard Therapeutics Announces the Filing and Validation of Marketing Authorization Application by European Medicines Agency for OTL-200 for the Treatment of Metachromatic LeukodystrophyApplication Being Evaluated Under Accelerated Assessment
12/2/2019
Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorization Application (MAA) for OTL-200,